Do allogeneic DCG promote lung NK cell activation and antitumor effect after invariant NKT cell activation?
This allogeneic DCG treatment could be substituted for syngeneic DCG treatment. The results obtained in the present study suggest that allogeneic DCG treatment may provide a new approach in cancer immunotherapy with NKT cells.
Low anti-PC levels increase the risk of CVE in men. This effect may be partly mediated by a fast C-IMT progression.